Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06852495
Active, not recruiting Observational

the Effect of Environmental Factors on Colorectal Cancer Based on Macrogenomes

NCT06852495 · tracked via the Priya Life Science China tracker
Sponsor
Dong Peng
Phase
Observational
Started
2024-11-01
Last updated
2025-02-28

Condition(s) studied

Colon CancerRectal Cancer

Study summary

The aim of this study is to investigate the effects of environmental factors, such as air pollution, on the occurrence, development and prognosis of colorectal cancer; to identify metabolic markers specific to colorectal cancer patients, which will provide a basis for early diagnosis, early intervention and individualized treatment; and to comprehensively understand the mechanism of the occurrence and development of colorectal cancer by integrating the data of environmental factors and the macro-genome, and to develop new predictive and therapeutic strategies.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Age ≥18 years old; * Patients diagnosed with colorectal cancer by pathologic biopsy before surgery; * Patients did not undergo chemotherapy, radiotherapy, targeted and immunotherapy, etc. before enrollment; * Willing to participate in the study and sign an informed consent form. Complete clinical data. Exclusion Criteria: * Concurrent primary malignant tumor other than colorectal cancer; * Patients with severe cardiopulmonary insufficiency or other systemic diseases that affect the choice of treatment plan; * Inappropriate for enrollment as assessed by the investigator; * Incomplete clinical data.

Primary outcome measure(s)

  • prognosis — From date of diagnosis until the date of death from any cause or or loss to follow-up, whichever came first, assessed up to 60 months
    Overall survival (OS), from date of diagnosis until the date of death from any cause or or loss to follow-up, whichever came first.

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Chongqing Medical University Chongqing Chongqing Municipality

More Dong Peng trials in China

Microplastics in Paraneoplastic and Intratumoral for Colorectal Cancer Active, not recruiting
The Effect of Environmental Factors on Gastric Cancer Based on Macrogenome Active, not recruiting
Impact of Pre- and Post-operative Serum Metabolome Dynamics in Colorectal Resection Outcomes Active, not recruiting
Impact of Environmental Factors and Metabolomics on Colorectal Cancer. Active, not recruiting
Predictive Value of Air Pollution and Metabolomics for Gastric Cancer. Active, not recruiting

Other trials for the same condition

A Study on the Accurate Evaluation of Pseudoprogression of Rectal Cancer Immunotherapy Based on Multitemporal and Multiparameter MRI Recruiting
Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer Recruiting
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer Active, not recruiting
Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy Recruiting
Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06852495 on ClinicalTrials.gov ↗ ← All trials in China